The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
(1999) · PubMed · Cited by 2,204
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Cancer's Molecular Sweet Tooth and the Warburg Effect
Kim, J.-W., & Dang, C. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1501 · Cited by 1,215
Energy metabolism in tumor cells
Moreno‐Sánchez, R., Rodríguez‐Enríquez, S., Marín‐Hernández, A., & Saavedra, E. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.05686.x · Cited by 1,082
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc
Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., & Dang, C. V. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000023200 · Cited by 879
Cited by
The metabolic signature of macrophage responses
Viola, A., Munari, F., Sánchez-Rodríguez, R., Scolaro, T., & Castegna, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01462 · Cited by 2,021
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Role of PFKFB3-Driven Glycolysis in Vessel Sprouting
De Bock, K., Georgiadou, M., Schoors, S., Kuchnio, A., Wong, B. W., Cantelmo, A. R., Quaegebeur, A., Ghesquière, B., Cauwenberghs, S., Eelen, G., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.037 · Cited by 1,551
Self-citationTargeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Links between metabolism and cancer
Dang, C. V. (2012) · Genes & Development · doi:10.1101/gad.189365.112 · Cited by 1,100
Rodríguez-Prados, J.-C., Través, P. G., Cuenca, J., Rico, D., Aragonés, J., Martín-Sanz, P., Cascante, M., & Boscá, L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901698 · Cited by 1,022
Cancer Cell Metabolism: One Hallmark, Many Faces
Cantor, J. R., & Sabatini, D. M. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0345 · Cited by 947
Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
Feng, J., Li, J., Wu, L., Yu, Q., Ji, J., Wu, J., Dai, W., & Guo, C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01629-4 · Cited by 699
Phosphofructokinase 1 Glycosylation Regulates Cell Growth and Metabolism
Yi, W., Clark, P. M., Mason, D. E., Keenan, M. C., Hill, C., Goddard, W. A., Peters, E. C., Driggers, E. M., & Hsieh-Wilson, L. C. (2012) · Science · doi:10.1126/science.1222278 · Cited by 676
Targeting immunometabolism as an anti-inflammatory strategy
Pålsson-McDermott, E. M., & O’Neill, L. A. J. (2020) · Cell Research · doi:10.1038/s41422-020-0291-z · Cited by 577
Mechanical regulation of glycolysis via cytoskeleton architecture
Park, J. S., Burckhardt, C. J., Lazcano, R., Solis, L. M., Isogai, T., Li, L., Chen, C. S., Gao, B., Minna, J. D., Bachoo, R., et al. (2020) · Nature · doi:10.1038/s41586-020-1998-1 · Cited by 575
Williams, N. C., & O’Neill, L. A. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00141 · Cited by 570
Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis
Schoors, S., De Bock, K., Cantelmo, A. R., Georgiadou, M., Ghesquière, B., Cauwenberghs, S., Kuchnio, A., Wong, B. W., Quaegebeur, A., Goveia, J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.11.008 · Cited by 529
Self-citationChanges in Nutritional Status Impact Immune Cell Metabolism and Function
Alwarawrah, Y., Kiernan, K., & MacIver, N. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01055 · Cited by 513
Diaz-Ruiz, R., Rigoulet, M., & Devin, A. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.08.010 · Cited by 486
Aerobic glycolysis tunes YAP/TAZ transcriptional activity
Enzo, E., Santinon, G., Pocaterra, A., Aragona, M., Bresolin, S., Forcato, M., Grifoni, D., Pession, A., Zanconato, F., Guzzo, G., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490379 · Cited by 414
“…PFKFB3 is the isoform displaying the highest F6P to F2,6P kinase activity and which potently promotes PFK1 activity (Herrero-Mendez et al , 2009; Yalcin et al , 2009; De Bock et al , 2013); in line with our biochemical findings, PFKFB3 dose-dependently enhanced YAP/TAZ transcriptional activity…”
Targeting cell cycle regulation in cancer therapy
Diaz-Moralli, S., Tarrado-Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 361
Glycolysis: a bioenergetic or a survival pathway?
Bolaños, J. P., Almeida, A., & Moncada, S. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.10.006 · Cited by 359
Yang, Z., Fujii, H., Mohan, S. V., Goronzy, J. J., & Weyand, C. M. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130252 · Cited by 334
“As a gatekeeper in the metabolic degradation of glu cose, PFK1 is controlled by downstream metabolites, most im portantly by its allosteric activator fructose 2,6bisphosphate (F2,6BP; Van Schaftingen et al., 1980).”
BackgroundInfluentialZhong, X., He, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01358-5 · Cited by 329
Control of Glycolysis through Regulation of PFK1: Old Friends and Recent Additions
Mor, I., Cheung, E. C., & Vousden, K. H. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010868 · Cited by 316
New aspects of the Warburg effect in cancer cell biology
Bensinger, S. J., & Christofk, H. R. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.02.003 · Cited by 307
Dysregulated metabolism contributes to oncogenesis
Hirschey, M. D., DeBerardinis, R. J., Diehl, A. M. E., Drew, J. E., Frezza, C., Green, M. F., Jones, L. W., Ko, Y. H., Le, A., Lea, M. A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.10.002 · Cited by 305
The Warburg Effect 97 Years after Its Discovery
Pascale, R. M., Calvisi, D. F., Simile, M. M., Feo, C. F., & Feo, F. (2020) · Cancers · doi:10.3390/cancers12102819 · Cited by 300
Citrate – new functions for an old metabolite
Iacobazzi, V., & Infantino, V. (2014) · Biological Chemistry · doi:10.1515/hsz-2013-0271 · Cited by 285
Cancer metabolism: The Warburg effect today
Ferreira, L. M. R. (2010) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2010.08.006 · Cited by 281
Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer
Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0097 · Cited by 276
Self-citationThe Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Ros, S., & Schulze, A. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-8 · Cited by 269
AMPK: A Contextual Oncogene or Tumor Suppressor?
Liang, J., & Mills, G. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3876 · Cited by 252
Fructose-1,6-bisphosphate couples glycolytic flux to activation of Ras
Peeters, K., Van Leemputte, F., Fischer, B., Bonini, B. M., Quezada, H., Tsytlonok, M., Haesen, D., Vanthienen, W., Bernardes, N., Gonzalez-Blas, C. B., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01019-z · Cited by 203
Immunometabolism in the development of rheumatoid arthritis
Weyand, C. M., & Goronzy, J. J. (2020) · Immunological Reviews · doi:10.1111/imr.12838 · Cited by 193
Almeida, A., Bolaños, J. P., & Moncada, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913668107 · Cited by 166
Ahuja, P., Zhao, P., Angelis, E., Ruan, H., Korge, P., Olson, A., Wang, Y., Jin, E. S., Jeffrey, F. M., Portman, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci38331 · Cited by 157
“These include ENO-1α, HK-2, LDHA, and glucose transporter I, as well as PFK, defined as the rate-limiting enzyme for glycolysis in the hypertrophied heart (15, 27, 44, 45).”
BackgroundTargeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Cerebral gluconeogenesis and diseases
Yip, J., Geng, X., Shen, J., & Ding, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00521 · Cited by 89
Zhao, J., Jin, D., Huang, M., Ji, J., Xu, X., Wang, F., Zhou, L., Bao, B., Jiang, F., Xu, W., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1416472 · Cited by 84
“Fructose-2,6-bisphosphate, the catalytic product of PFK2, is an allosteric activator of PFK1, and tumor cells indirectly control the activity of PFK1 by upregulating PFK2 expression, which in turn promotes glycolysis (Yalcin et al., 2009; Bartrons et al., 2018).”
BackgroundTargeted Cancer Therapy with a 2-Deoxyglucose-Based Adriamycin Complex
Cao, J., Cui, S., Li, S., Du, C., Tian, J., Wan, S., Qian, Z., Gu, Y., Chen, W. R., & Wang, G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2072 · Cited by 84
Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective
Missiaen, R., Morales-Rodriguez, F., Eelen, G., & Carmeliet, P. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.001 · Cited by 58
Maddalena, F., Condelli, V., Matassa, D. S., Pacelli, C., Scrima, R., Lettini, G., Li Bergolis, V., Pietrafesa, M., Crispo, F., Piscazzi, A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12814 · Cited by 38
Johnson, M., Chung, E., Yang, H., Xing, H., & Carroll, R. (2015) · Cancer Translational Medicine · doi:10.4103/2395-3977.168575 · Cited by 4
Metadata
- Authors
- Yalcin, A., Telang, S., Clem, B., & Chesney, J.
- Venue
- Experimental and Molecular Pathology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 86
- Issue
- 3
- Pages
- 174-179
- ISSN
- 0014-4800 (ISSN-L)
- OpenAlex
- W1989760304
- Cited by
- 405
- References
- 71
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.